Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug in another study.

Robert F. Kennedy Jr., Trump's pick to head the Department of Health and Human Services, faces scrutiny for fees he may earn ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Merck on Friday said the recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use covers the 21-valent conjugate vaccine for immunization for the prevention ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Kennedy Jr. earned more than $2.4 million as a consultant referring cases to the law firm Wisner Baum, government records show. Wisner Baum is suing Merck & Co. over allegations that the ...

Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, as ...

Merck must face trial on a Black IT director’s claims that racial bias drove his firing after he ordered the removal of a White contractor from a project, a New York federal judge ruled.

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...